



Human Anti-Natalizumab monoclonal antibody, clone AbD21375 (CABT-ZB1173)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Natalizumab
Target	Natalizumab
Immunogen	Natalizumab
Isotype	Fab
Source/Host	Human
Species Reactivity	N/A
Clone	AbD21375
Affinity Constant	The monovalent intrinsic affinity of this antibody was measured as $K_D = 2.1$ nM by real time, label free molecular interaction analysis on immobilized natalizumab.
Purification	Metal chelate affinity chromatography
Conjugate	Unconjugated
Applications	Suitable for PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB1173 - CABT-ZB1174 / CABT-ZB1175 Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Liquid
Concentration	Lot specific

Size	100 µg
Buffer	PBS
Preservative	0.01% Thiomersal
Storage	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Ship	Wet ice

BACKGROUND

Introduction	Natalizumab (Tysabri) is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn's disease. It is directed against alpha-4 integrin (CD49d), and binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes, except neutrophils. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.
Keywords	Natalizumab; Tysabri